Abciximab improves 6-month clinical outcome after rescue coronary angioplasty

被引:49
作者
Petronio, AS [1 ]
Musumeci, G [1 ]
Limbruno, U [1 ]
De Carlo, M [1 ]
Baglini, R [1 ]
Paterni, G [1 ]
Delle Donne, MG [1 ]
Caravelli, P [1 ]
Nardi, C [1 ]
Mariani, M [1 ]
机构
[1] Univ Pisa, Cardiothorac Dept, Osped Cisanello, I-56124 Pisa, Italy
关键词
D O I
10.1067/mhj.2002.119762
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Few data are available concerning the effects on clinical outcome and left ventricular function of abciximab administration in patients undergoing rescue percutaneous transluminal coronary angioplasty (PTCA) after failed thrombolysis for acute myocardial infarction. The aim of the study was to investigate such effects. Methods Eighty-nine consecutive patients referred to our laboratory from other hospitals for rescue PTCA within 24 hours from the onset of chest pain were prospectively randomized before the procedure to abciximab treatment (44 patients) or placebo (45 patients). No significant differences in baseline characteristics were observed between the 2 groups. Study end points were the occurrence of major adverse cardiac events (MACE) such as death, reinfarction, congestive heart failure, target lesion revascularization, or recurrent ischemia at 30-day and 6-month follow-up and the occurrence of periprocedural bleeding. Results Mean time from symptom onset to reperfusion was 8.5 +/- 5.4 hours; rescue PTCA was successful in 96% of patients. The incidence of major, moderate, and minor bleeding was similar in the 2 groups. At 30-day follow-up, the echocardiographic left ventricular wall motion score index showed a significantly higher improvement in the abciximob group versus the placebo group (P < .001). At 6-month follow-up, the incidence of MACE was 11% in the abciximab group versus 38% in the placebo group (P = .004). Abciximab administration (P = .003) and cardiogenic shock (P = .005) were the only independent predictors of the occurrence of MACE at multivariable analysis. Conclusion Treatment with abciximab during rescue PTCA positively affects clinical outcome at 6-month follow-up without increasing periprocedural bleeding.
引用
收藏
页码:334 / 341
页数:8
相关论文
共 30 条
[1]   A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction - Results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial [J].
Antoniucci, D ;
Santoro, GM ;
Bolognese, L ;
Valenti, R ;
Trapani, M ;
Fazzini, PF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (06) :1234-1239
[2]   Primary coronary infarct artery stenting in acute myocardial infarction [J].
Antoniucci, D ;
Valenti, R ;
Santoro, GM ;
Bolognese, L ;
Trapani, M ;
Moschi, G ;
Fazzini, PF .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (05) :505-510
[3]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[4]  
Betriu A, 1997, NEW ENGL J MED, V336, P1621
[5]   Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction [J].
Brener, SJ ;
Barr, LA ;
Burchenal, JEB ;
Katz, S ;
George, BS ;
Jones, AA ;
Cohen, ED ;
Gainey, PC ;
White, HJ ;
Cheek, HB ;
Moses, JW ;
Moliterno, DJ ;
Effron, MB ;
Topol, EJ .
CIRCULATION, 1998, 98 (08) :734-741
[6]  
Campbell KR, 2000, AM J CARDIOL, V85, p32C
[7]   Potential non-glycoprotein IIb IIIa effects of abciximab [J].
Coller, BS .
AMERICAN HEART JOURNAL, 1999, 138 (01) :S1-S5
[8]   RANDOMIZED COMPARISON OF RESCUE ANGIOPLASTY WITH CONSERVATIVE MANAGEMENT OF PATIENTS WITH EARLY FAILURE OF THROMBOLYSIS FOR ACUTE ANTERIOR MYOCARDIAL-INFARCTION [J].
ELLIS, SG ;
DASILVA, ER ;
HEYNDRICKX, G ;
TALLEY, JD ;
CERNIGLIARO, C ;
STEG, G ;
SPAULDING, C ;
NOBUYOSHI, M ;
ERBEL, R ;
VASSANELLI, C ;
TOPOL, EJ .
CIRCULATION, 1994, 90 (05) :2280-2284
[9]   Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: Insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences [J].
Ellis, SG ;
da Silva, ER ;
Spaulding, CM ;
Nobuyoshi, M ;
Wiener, B ;
Talley, JD .
AMERICAN HEART JOURNAL, 2000, 139 (06) :1046-1053
[10]   Incidence, consequences, and risk factors of early reocclusion after primary and/or rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction [J].
Garot, P ;
Himbert, D ;
Juliard, JM ;
Golmard, JL ;
Steg, PG .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (05) :554-558